Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety

Journal of Clinical Psychopharmacology

Volumn 19, Issue 2, 1999, Pages 125-131

  Smith, Ward T ^a,b,d   Londborg, Peter D ^a,b   Blomgren, Sharon L ^c   Tollefson, Gary D ^c   Sayler, Mary E ^c  

^a Summit Research Network   (United States)

^b Summit Research Network   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Pac Northwest Clin Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; ZATOSETRON MALEATE;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HAMILTON SCALE; HUMAN; LABORATORY TEST; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANXIETY DISORDERS; BENZOFURANS; BICYCLO COMPOUNDS, HETEROCYCLIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN ANTAGONISTS;

EID: 0032951421     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199904000-00006     Document Type: Article

References (20)

1. 3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem 1992;35:310-9.
2. 3 receptor antagonists. Drugs Future 1989;14:875-9.
3. 3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 1989;10:127-9.
4. 3 receptor antagonist, GR 38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987;92:881-94.
5. 3 receptors. Pharmacol Toxicol 1992;71:401-5.
6. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
7. Derogatis LR. SCL-90-R. Minneapolis: National Computer Systems, Inc., 1975;55440.
8. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
9. Guy W. ECDEU assessment manual for psychopharmacology, revised. U.S. Department of Health, Education, and Welfare, publication no. (ADM) 76-338. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch, National Institute of Mental Health, 1976:215-22.
10. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46:326-31.
11. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines: effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899-907.
12. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr Scand Suppl 1987;334: 83-92.
13. Declaration of Helsinki. Bull Pan Am Health Organ 1990;24:606-9.
14. Riskind JH, Beck AT, Brown G, Steer RA. Taking, the measure of anxiety and depression. Validity of the reconstructed Hamilton scales. J Nerv Ment Dis 1987;175:474-9.
15. Koeter MW, van den Brink W. The relationship between depression and anxiety: construction of a prototypical anxiety and depression scale. Psychol Med 1992;22:597-606.
16. Miyata K, Honda K. Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles. Nippon Yakurigaku Zasshi 1994; 104:143-52.
17. Angst J. Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry Suppl 1996;30:31-7.
18. Brawman-Mintzer O, Lydiard RB, Emmanuel N, Payeur R, Johnson M, Roberts J, Jarrell MP, Ballenger JC. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993;150:1216-8.
19. Duberstein PR. The issue of side effects and the "blind ability" of clinical drug trials [comment]. Am J Psychiatry 1993; 150:1760.
20. White K, Kando J, Park T, Waternaux C, Brown WA. Side effects and "blindability" of clinical drug trials. Am J Psychiatry 1992; 149:1730-1.